Compare Amylx Pharmaceuticals Inc (AMLX) vs IAC/Interactivecorp (PPLI) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

PPLI trades at $46.50, down 2.13% on the day, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, revenue has declined from $5.2B in 2022 to $2.4B in 2025, with recent quarters missing EPS expectations. The company maintains a high gross margin of 66.49% but struggles with profitability, posting a net loss of $104M in 2025. Analyst consensus remains bullish with a $55.40 price target, while recent news questions valuation after a 3.6% rally.

PPLI presents a mixed outlook with bullish analyst sentiment against challenging fundamentals. The 63.64% buy rating and 25% upside to consensus target reflect optimism for a turnaround, but consecutive earnings misses and negative cash flow pose significant execution risks. Investors face volatility from inconsistent profitability despite attractive valuation metrics like P/B of 0.76. The key catalyst remains demonstrating sustainable earnings growth amid declining revenues.